bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
229 hedge funds and large institutions have $1.59B invested in bluebird bio in 2021 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 64 reducing their positions, and 78 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 64
1.21% less ownership
Funds ownership: 7.24% → 6.03% (-1.2%)
13% less funds holding
Funds holding: 262 → 229 (-33)
38% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 78
42% less capital invested
Capital invested by funds: $2.73B → $1.59B (-$1.14B)
44% less call options, than puts
Call options by funds: $25.8M | Put options by funds: $45.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$59.6M |
| 2 |
AC
Armistice Capital
New York
|
+$41.3M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$33.3M |
| 4 |
SC
Sessa Capital
New York
|
+$33.3M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$30.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$352M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$137M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$135M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$48.8M |
| 5 |
CC
Casdin Capital
New York
|
-$39.6M |
BLUE Hedge Fund Activity: Q1 2021 in Review
229 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2021, worth a combined $1.59B — down 42% from $2.73B a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of BLUE and 48 opened new positions — a net loss of 30 holders — while 64 trimmed existing stakes and 85 added.
The largest buyer was Wellington Management Group, adding an estimated $59.6M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $352M sold.
- 229 institutional investors held bluebird bio (BLUE) as of Q1 2021, down from 262 in Q4 2020.
- Funds reported $1.59B of bluebird bio stock for Q1 2021, down 42% quarter-over-quarter.
- 48 funds opened new bluebird bio positions in Q1 2021 and 78 closed out, a net change of -30 holders.
- The largest bluebird bio buyer in Q1 2021 was Wellington Management Group, an estimated $59.6M added.
- The largest bluebird bio seller in Q1 2021 was Capital Research Global Investors, an estimated $352M sold.
Based on aggregated 13F filings for Q1 2021.